header logo image


Page 179«..1020..178179180181..190200..»

Healthcare Nanotechnology (Nanomedicine) Market Trend, Technology Innovations and Growth Prediction 2021-2027 The Manomet Current – The Manomet…

August 17th, 2021 1:53 am

The research analysis of Healthcare Nanotechnology (Nanomedicine) market offers significant information regarding the major trends that define this business landscape with regards to the regional outlook and competitive scenario. The report also highlights the limitations & challenges that could hamper the industry remuneration alongside the key opportunities that will aid in business expansion. Moreover, the document provides crucial insights regarding the effect of COVID-19 pandemic on the overall market outlook.

This report contains market size and forecasts of Healthcare Nanotechnology (Nanomedicine) in Global, including the following market information:Global Healthcare Nanotechnology (Nanomedicine) Market Revenue, 2016-2021, 2022-2027, ($ millions)Global top five companies in 2020 (%)

The global Healthcare Nanotechnology (Nanomedicine) market was valued at 200560 million in 2020 and is projected to reach US$ 285060 million by 2027, at a CAGR of 9.2% during the forecast period.Research has surveyed the Healthcare Nanotechnology (Nanomedicine) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Download PDF Sample of Healthcare Nanotechnology (Nanomedicine) Market report @ https://www.themarketinsights.com/request-sample/253870

Total Market by Segment:Global Healthcare Nanotechnology (Nanomedicine) Market, By Type, 2016-2021, 2022-2027 ($ millions)Global Healthcare Nanotechnology (Nanomedicine) Market Segment Percentages, By Type, 2020 (%)NanomedicineNano Medical DevicesNano DiagnosisOther

China Healthcare Nanotechnology (Nanomedicine) Market, By Application, 2016-2021, 2022-2027 ($ millions)China Healthcare Nanotechnology (Nanomedicine) Market Segment Percentages, By Application, 2020 (%)AnticancerCNS ProductAnti-infectiveOther

Global Healthcare Nanotechnology (Nanomedicine) Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)Global Healthcare Nanotechnology (Nanomedicine) Market Segment Percentages, By Region and Country, 2020 (%)North AmericaUSCanadaMexicoEuropeGermanyFranceU.K.ItalyRussiaNordic CountriesBeneluxRest of EuropeAsiaChinaJapanSouth KoreaSoutheast AsiaIndiaRest of AsiaSouth AmericaBrazilArgentinaRest of South AmericaMiddle East & AfricaTurkeyIsraelSaudi ArabiaUAERest of Middle East & Africa

Report Customization available as per requirements Request Customization@ https://www.themarketinsights.com/request-customization/253870

Competitor AnalysisThe report also provides analysis of leading market participants including:Total Healthcare Nanotechnology (Nanomedicine) Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)Total Healthcare Nanotechnology (Nanomedicine) Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:AmgenTeva PharmaceuticalsAbbottUCBRocheCelgeneSanofiMerck & CoBiogenStrykerGilead SciencesPfizer3M CompanyJohnson & JohnsonSmitH& NephewLeadiant BiosciencesKyowa Hakko KirinTakedaIpsenEndo International

To Check Discount @ https://www.themarketinsights.com/check-discount/253870

Table of ContentChapter One: Introduction to Research & Analysis Reports

Chapter Two: Global Healthcare Nanotechnology (Nanomedicine) Overall Market Size

Chapter Three: Company Landscape

Chapter Four: Market Sights by Product

Chapter Five: Sights by Application

Chapter Six: Sights by Region

Chapter Seven: Players Profiles

Chapter Eight: Conclusion

Chapter Nine: Appendix9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List of Table and FigureTable 1. Healthcare Nanotechnology (Nanomedicine) Market Opportunities & Trends in Global Market

Table 2. Healthcare Nanotechnology (Nanomedicine) Market Drivers in Global Market

Table 3. Healthcare Nanotechnology (Nanomedicine) Market Restraints in Global Market

Table 4. Key Players of Healthcare Nanotechnology (Nanomedicine) in Global Market

Table 5. Top Healthcare Nanotechnology (Nanomedicine) Players in Global Market, Ranking by Revenue (2019)

Table 6. Global Healthcare Nanotechnology (Nanomedicine) Revenue by Companies, (US$, Mn), 2016-2021

Table 7. Global Healthcare Nanotechnology (Nanomedicine) Revenue Share by Companies, 2016-2021

Table 8. Global Companies Healthcare Nanotechnology (Nanomedicine) Product Type

Table 9. List of Global Tier 1 Healthcare Nanotechnology (Nanomedicine) Companies, Revenue (US$, Mn) in 2020 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Healthcare Nanotechnology (Nanomedicine) Companies, Revenue (US$, Mn) in 2020 and Market Share

Table 11. By Type Global Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2021 VS 2027

Table 12. By Type Healthcare Nanotechnology (Nanomedicine) Revenue in Global (US$, Mn), 2016-2021

Table 13. By Type Healthcare Nanotechnology (Nanomedicine) Revenue in Global (US$, Mn), 2022-2027

Table 14. By Application Global Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2021 VS 2027

Table 15. By Application Healthcare Nanotechnology (Nanomedicine) Revenue in Global (US$, Mn), 2016-2021

Table 16. By Application Healthcare Nanotechnology (Nanomedicine) Revenue in Global (US$, Mn), 2022-2027

Table 17. By Region Global Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2021 VS 2027

Table 18. By Region Global Healthcare Nanotechnology (Nanomedicine) Revenue (US$, Mn), 2016-2021

Table 19. By Region Global Healthcare Nanotechnology (Nanomedicine) Revenue (US$, Mn), 2022-2027

Table 20. By Country North America Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2016-2021

Table 21. By Country North America Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2022-2027

Table 22. By Country Europe Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2016-2021

Table 23. By Country Europe Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2022-2027

Table 24. By Region Asia Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2016-2021 continued

About us.The Market Insights is a sister company to SI Market research and The Market Insights is into reselling. The Market Insights is a company that is creating cutting edge, futuristic and informative reports in many different areas. Some of the most common areas where we generate reports are industry reports, country reports, company reports and everything in between. At The Market Insights, we give our clients the best reports that can be made in the market. Our reports are not only about market statistics, but they also contain a lot of information about new and niche company profiles. The companies that feature in our reports are pre-eminent. The database of the reports on market research is constantly updated by us. This database contains a broad variety of reports from the cardinal industries. Our clients have direct access online to our databases. This is done to ensure that the client is always provided with what they need. Based on these needs, we at The Market Insights also include insights from experts about the global industries, market trends as well as the products in the market. These resources that we prepare are also available on our database for our esteemed clients to use. It is our duty at The Market Insights to ensure that our clients find success in their endeavors and we do everything that we can to help make that possible.

Direct ContactJessica Joyal+91-9284395731 | +91 9175986728sales@themarketinsights.com

See the rest here:
Healthcare Nanotechnology (Nanomedicine) Market Trend, Technology Innovations and Growth Prediction 2021-2027 The Manomet Current - The Manomet...

Read More...

Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc. – PRNewswire

August 17th, 2021 1:53 am

SAN FRANCISCO, Aug. 12, 2021 /PRNewswire/ --The global regenerative medicine marketsize is expectedto reach USD 57.08 billion by 2027, growing at a CAGR of 11.27% over the forecast period, according to a new report by Grand View Research, Inc. Recent advancements in biological therapies have resulted in a gradual shift in preference toward personalized medicinal strategies over the conventional treatment approach. This has resulted in rising R&D activities in the regenerative medicine arena for the development of novel regenerative therapies.

Key Insights & Findings:

Read 273 page research report, "Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Cell-based Immunotherapies, Gene Therapies), By Therapeutic Category (Cardiovascular, Oncology), And Segment Forecasts, 2021 - 2027", by Grand View Research

Furthermore,advancements in cell biology, genomics research, and gene-editing technology are anticipated to fuel the growth of the industry. Stem cell-based regenerative therapies are in clinical trials, which may help restore damaged specialized cells in many serious and fatal diseases, such as cancer, Alzheimer's, neurodegenerative diseases, and spinal cord injuries. For instance, various research institutes have adopted Human Embryonic Stem Cells (hESCs) to develop a treatment for Age-related Macular Degeneration (AMD).

Constant advancements in molecular medicines have led to the development of gene-based therapy, which utilizes targeted delivery of DNA as a medicine to fight against various disorders. Gene therapy developments are high in oncology due to the rising prevalence and genetically driven pathophysiology of cancer. The steady commercial success of gene therapies is expected to accelerate the growth of the global market over the forecast period.

Grand View Research has segmented the global regenerative medicine market on the basis of product, therapeutic category, and region:

List of Key Players of Regenerative Medicine Market

Check out more studies related to Global Biotechnology Industry, conducted by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: 1-415-349-0058Toll Free: 1-888-202-9519Email: [emailprotected]Web: https://www.grandviewresearch.comFollow Us: LinkedIn| Twitter

SOURCE Grand View Research, Inc.

Go here to see the original:
Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc. - PRNewswire

Read More...

Nanotechnology Market Share, Industry Size, Leading Companies Outlook, Upcoming Challenges and Opportunities till 2028 – The Market Writeuo – The…

August 17th, 2021 1:53 am

The Latest research study released by DBMR Global Nanotechnology Market with 350+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth. The report shows market share, size, trends, growth, trends, applications, competition analysis, development patterns, and the correlations between the market dynamics and forecasts for 2020 to 2027 time-frames. The report aims to provide an overview of global Nanotechnology Market with detailed market segmentation by product/application and geography. The report provides key statistics on the Market status of the players and offers key trends and opportunities in the market. Research report has been compiled by studying the market in-depth along with drivers, opportunities, restraints & other strategies as well as new-developments that can help a reader to understand the exact situation of the market along with the factors that can limit or hamper the market growth and the report also has been updated with Impacts & effects of Coronavirus pandemic and how it has influenced consumer behavior& the growth of the market as well as industries.

The Global Nanotechnology Market is expected to reach USD 24.56 billion by 2025, from USD 7.24 billion in 2017 growing at a CAGR of 16.5% during the forecast period of 2020 to 2025

Download Free Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this [emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanotechnology-market&ab

Nanoscience is the study of extremely small things. The development of nanotechnology is being growing in many fields, as it has various applications, such as in chemistry, biology, physics, materials science and engineering. Nanotechnology deals with the use of nanoparticle of size of 1 to 100 nm to be used in all major field of medical. Materials designed from nanotechnology are lighter, stronger and more durable. In oncology research, nanotechnology assists in cancer eradication. Nanotechnology based device are also used in fitness monitoring. Smartphone apps and bracelets are developed based on nanotechnology concept. A nano based device is used to sense the body temperature, heartbeat and others which are sent back to the reader. After analysing the temperature and heartbeat, medical staff monitors the condition. All these nano based devices helps to drive the market. For elder people, battery-free printed graphene sensors are also developed which helps in gathering the health condition of the elder population, enables remote healthcare and improves the quality of life. In diagnostic and prevention, nanotechnology plays a vital role in cancer diagnostics. Nanotechnology based devices can detects the biomarker produced by the circulating tumor cells (CTCs) on the onset of cancer. Based on nanotechnology, two main methods of circulating tumor cells (CTC) isolations are magnetic and microfluidic methods. In clinical development fluorescent nano sensors are used for in-vivo monitoring of biomarkers. Another application of nanotechnology is nanomedicine which has potential application in diagnosis and therapy medicine for regeneration of tissues and organs.

This Nanotechnology Market 2020 Reportencompasses an infinite knowledge and information on what the markets definition, classifications, applications, and engagements are and also explains the drivers and restraints of the market which is obtained from SWOT analysis. By applying market intelligence for this Nanotechnology Market report, industry expert measure strategic options, summarize successful action plans and support companies with critical bottom-line decisions. Additionally, the data, facts and figures collected to generate this market report are obtained forms the trustworthy sources such as websites, journals, mergers, newspapers and other authentic sources. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.

According to this reportGlobal Nanotechnology Marketwill rise from Covid-19 crisis at moderate growth rate during 2020 to 2027. Nanotechnology Market includes comprehensive information derived from depth study on Nanotechnology Industry historical and forecast market data. Global Nanotechnology Market Size To Expand moderately as the new developments in Nanotechnology and Impact of COVID19 over the forecast period 2020 to 2027.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT, GET FREE COVID-19 SAMPLE @https://www.databridgemarketresearch.com/covid-19-impact/global-nanotechnology-market?ab

Nanotechnology Market report provides depth analysis of the market impact and new opportunities created by theCOVID19/CORONAVirus pandemic. Report covers Nanotechnology Market report is helpful for strategists, marketers and senior management, And Key Players in Nanotechnology Industry.

List of Companies Profiled in the Nanotechnology Market Report are:

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @https://www.databridgemarketresearch.com/toc/?dbmr=global-nanotechnology-market&Ab

Nanotechnology Reportdisplays data on key players, majorcollaborations, merger & acquisitions along with trending innovation and business policies. The report highlights current and future market trends and carries out analysis of the effect of buyers, substitutes, new entrants, competitors, and suppliers on the market. The key topics that have been explained in this Nanotechnology market report include market definition, market segmentation, key developments, competitive analysis and research methodology. To accomplish maximum return on investment (ROI), its very essential to be acquainted with market parameters such as brand awareness, market landscape, possible future issues, industry trends and customer behavior where this Nanotechnology report comes into play.

The Segments and Sub-Section of Nanotechnology Market are shown below:

By Type (Nano composites, Nano materials, Nano tools, Nano devices, Others)

By Applications (Healthcare, Environment, Energy, Food & Agriculture, Information & Technology, Others)

By Industry (Electronics, Cosmetics, Pharmaceutical, Biotechnology, Others

Market Size Segmentation by Region & Countries (Customizable):

Key questions answered

What impact does COVID-19 have made on Global Nanotechnology Market Growth & Sizing?

Who are the Leading key players and what are their Key Business plans in the Global Nanotechnology market?

What are the key concerns of the five forces analysis of the Global Nanotechnology market?

What are different prospects and threats faced by the dealers in the Global Nanotechnology market?

What are the strengths and weaknesses of the key vendors?

Market Segmentation: Global Nanotechnology Market

The global nanotechnology market is segmented based on product type, application, industry and geographical segments.

By Product Type (Nano Composites, Nano Materials, Nano Tools, Nano Devices, Others), By Applications (Healthcare, Environment, Energy, Food & Agriculture, Information & Technology, Others), By Industry (Electronics, Cosmetics, Pharmaceutical, Biotechnology, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Based on product type , the market is segmented into nano-composites and nano materials, nano tools, nano devices, and others. Nano-composites are further sub segmented into nanoparticles, nanotubes and nano clays. Nano materials are further sub-segmented into nano fibers, nano ceramic products and nano magnetics. Nano tools are further sub-segmented into nanolithography tools and scanning probe microscopes. Nanodevices are further sub-segmented into nanosensors and nanoelectronics.

On the basis of application, the market is further segmented into healthcare, environment, energy, food & agriculture, information & technology and others.

Based on industries, the market is segmented into electronics, cosmetics, pharmaceutical, biotechnology and others.

Based on geography, the market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Strategic Points Covered in Table of Content of Global Nanotechnology Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Nanotechnology market

Chapter 2: Exclusive Summary the basic information of the Nanotechnology Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Nanotechnology

Chapter 4: Presenting the Nanotechnology Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region 2010-2019

Chapter 6: Evaluating the leading manufacturers of the Nanotechnology market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2020-2027).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Nanotechnology Market is a valuable source of guidance for individuals and companies in decision framework.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

AboutDataBridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Read more:
Nanotechnology Market Share, Industry Size, Leading Companies Outlook, Upcoming Challenges and Opportunities till 2028 - The Market Writeuo - The...

Read More...

Global Nanomedicine Market is Expected to Grow at an Impressive CAGR by 2028 The Manomet Current – The Manomet Current

August 17th, 2021 1:53 am

DBMR has added a new report titled Global Nanomedicine Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This Report performs the methodical and comprehensive market research study that puts forth the facts and figures linked with any subject about industry. It all-inclusively estimates general market conditions, the growth prospects in the market, possible restrictions, significant industry trends, market size, market share, sales volume and future trends. A team of skilled analysts, statisticians, research experts, enthusiastic forecasters, and economists work painstakingly to structure such a great market report for the businesses seeking a potential growth. A Global Nanomedicine Market analysis report is generated with the best and advanced tools of collecting, recording, estimating, and analyzing market data.

Major insights of the realistic Global Nanomedicine Market report are complete and distinct analysis of the market drivers and restraints, major market players involved like industry, detailed analysis of the market segmentation and competitive analysis of the key players involved. Market segmentation categorizes the market depending upon application, vertical, deployment model, end-user, and geography etc. This global market document also presents an idea about consumers demands, preferences, and their altering likings about particular product. Furthermore, big sample sizes have been utilized for the data collection in the winning Global Nanomedicine Market report which suits the necessities of small, medium, as well as large size of businesses.

Global nanomedicine market is registering a healthy CAGR of 15.50% in the forecast period of 2019-2026. This rise in the market value can be attributed to increasing number of applications and wide acceptance of the product globally. There is a significant rise in the number of researches done in this field which accelerate growth of nanomedicine market globally.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanomedicine-market

Key Market Competitors

Few of the major market competitors currently working in the global nanomedicine market are Abbott, Invitae Corporation, General Electric Company, Leadiant Biosciences, Inc., Johnson & Johnson Services, Inc., Mallinckrodt, Merck Sharp & Dohme Corp., NanoSphere Health Sciences, Inc., Pfizer Inc., CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Amgen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Luminex Corporation, Eli Lilly and Company, Nanobiotix, Sanofi, UCB S.A., Ablynx among others.

Competitive Landscape

Global Nanomedicine Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of nanomedicine market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Insights in the report:

Complete and distinct analysis of the market drivers and restraints

Key Market players involved in this industry

Detailed analysis of the Market Segmentation

Competitive analysis of the key players involved

Market Drivers are Restraints

Grab Your Report at an Impressive 30% Discount! Please click Here @ https://www.databridgemarketresearch.com/request-a-discount/global-nanomedicine-market

Market Segmentation:-

By Product Type

By Application

By Indication

By Modality

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

For More Insights Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-nanomedicine-market

Nanomedicine Market report effectively provides required features of the global market for the population and for the business looking people for mergers & acquisitions, making investments, new vendors or concerned in searching for the appreciated global market research facilities. It offers sample on the size, offer, and development rate of the market. The Nanomedicine report provides the complete structure and fundamental overview of the industry market.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

Here is the original post:
Global Nanomedicine Market is Expected to Grow at an Impressive CAGR by 2028 The Manomet Current - The Manomet Current

Read More...

Nanorobotics Market By Player, Region, Type, Application And Sales Channel, Regions, Type and Application, Revenue Market Forecast to 2028 – Digital…

August 17th, 2021 1:53 am

Rising investment in urgent care and increasing global geriatric population are key factors driving revenue growth of the global nanorobotics market

The globalNanorobotics marketsize is expected to reach USD 14.03 Billion in 2028 and register a CAGR of 10.9% over the forecast period, according to the latest report by Emergen Research. Nanorobotics market revenue growth is driven by key factors such as rapid innovations in nanorobotics technology and increasing application of the technology in treatment of neurological cardiovascular, oncological, infectious, orthopedic diseases, and others.

Nanorobotics is the technology which creates robots or machines at a very small scale. The field of nanorobotics brings together various disciplines, including nanofabrication processes used for producing nanoactuators, nanomotors, and nanosensors, among others. Rising focus on regenerative medicine coupled with technological advancements is boosting market revenue growth. Furthermore, increasing adoption of medical equipment and more advanced technologies such as Machine Learning (ML) and Artificial Intelligence (AI) is driving growth of the global nanorobotics market, and the trend is expected to continue going ahead.

Access full Report Description, TOC, Table of Figure, [emailprotected] https://www.emergenresearch.com/request-sample/744

Some Key Highlights From the Report

Key Growth Prospects:The report specializes in examining the major growth prospects of the global Nanorobotics market, such as new product launches, collaborations, joint ventures, mergers & acquisitions, agreements, partnerships, and the progress of the key market players functioning in the market, on regional and global levels.

The market intelligence report exhaustively examines the market value, share, demand, growth prospects, latest and historical trends, manufacturers, gross revenue collection, competitive terrain, market growth forecast, available products, and end-use applications.

Geographical Terrain of the Global Nanorobotics Market:

Please connect with our representative to get a Inquiry Of the Nanorobotics [emailprotected] https://www.emergenresearch.com/request-sample/744

For the purpose of this report, Emergen Research has segmented the global nanorobotics market based on type, application, and region:

To Get This Report At A Profitable [emailprotected] https://www.emergenresearch.com/request-discount/744

Table Of content

Chapter 1. Market Synopsis 1.1. Market Definition 1.2. Research Scope & Premise 1.3. Methodology 1.4. Market Estimation TechniqueChapter 2. Executive Summary 2.1. Summary Snapshot, 2020-2028Chapter 3. Indicative MetricsChapter 4. Nanorobotics Market Segmentation & Impact Analysis 4.1. Nanorobotics Market Material Segmentation Analysis 4.2. Industrial Outlook 4.2.1. Market indicators analysis 4.2.2. Market drivers analysis 4.2.2.1. Rising Focus on Nanotechnology and Regenerative Medicine 4.2.2.2. Increasing Government Support and Level of Investment in Nanorobotics 4.2.3. Market restraints analysis 4.2.3.1. Implementation of Excise Tax and Heavy Custom Duty on 4.3. Technological Insights 4.4. Regulatory Framework 4.5. ETOP Analysis 4.6. Porters Five Forces Analysis 4.7. Competitive Metric Space Analysis 4.8. Price trend Analysis 4.9. Customer Mapping 4.10. Covid-19 Impact Analysis 4.11. Global Recession Influence

Chapter 5. Nanorobotics Market By Type Insights & Trends 5.1. Type Dynamics & Market Share, 2021 & 2028 5.2. Nanomanipulator 5.2.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.3. Electron Microscope (EM) 5.2.3.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.3.3. Scanning Electron Microscope (SEM) 5.2.3.3.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.3.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.3.4. Transmission Electron Microscope (TEM) 5.2.3.4.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.3.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.4. Scanning Probe Microscope (SPM) 5.2.4.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.4.3. Atomic Force Microscopes (AFM) 5.2.4.3.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.4.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.4.4. Scanning Tunneling Microscope (STM) 5.2.4.4.1. Market estimates and forecast, 2018 2028 (USD Billion) 5.2.4.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.3. Bio-Nanorobotics 5.3.1. Market estimates and forecast, 2018 2028 (USD Billion) 5.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.4. Magnetically Guided 5.4.1. Market estimates and forecast, 2018 2028 (USD Billion) 5.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.5. Bacteria-Based 5.5.1. Market estimates and forecast, 2018 2028 (USD Billion) 5.5.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion)

Chapter 6. Nanorobotics Market By Application Insights & Trends 6.1. Application Dynamics & Market Share, 2021 & 2028 6.2. Nanomedicine 6.2.1. Market estimates and forecast, 2018 2028 (USD Billion) 6.2.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 6.3. Biomedical 6.3.1. Market estimates and forecast, 2018 2028 (USD Billion) 6.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 6.4. Mechanical 6.4.1. Market estimates and forecast, 2018 2028 (USD Billion) 6.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 6.5. Others (Space and Oil & Gas) 6.5.1. Market estimates and forecast, 2018 2028 (USD Billion) 6.5.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion)

Continue..!

Request customization of the report: https://www.emergenresearch.com/request-for-customization/744

Thank you for reading our report. For further details or to inquire about customization, please let us know, and we will offer you a report well-suited to your requirements.

Media ContactCompany Name: Emergen ResearchContact Person: Eric LeeEmail: Send EmailPhone: +1 (604) 757-9756Address:14671 110 Avenue Surrey, British Columbia, V3R2A9City: SurreyState: British ColumbiaCountry: CanadaWebsite: http://www.emergenresearch.com/industry-report/nanorobotics-market

Read the original post:
Nanorobotics Market By Player, Region, Type, Application And Sales Channel, Regions, Type and Application, Revenue Market Forecast to 2028 - Digital...

Read More...

Complementary Protection May Be at Hand With a COVID-19-Preventing Nasal Spray – Newsweek

August 17th, 2021 1:53 am

Vaccinated citizens can still transmit the COVID-19 virus and its variants to other people. Salvacion USA Inc. is therefore excited to introduce the development of a complementary product, designed for adults 18 and older, it hopes could accompany COVID-19 vaccines to offer additional protection: a nasal spray to shield the nasal passages and prevent further viral transmission. (However, CDC guidelines should still be followed, and those who are eligible should receive the COVID-19 vaccination.)

COVID-19 vaccination numbers in the U.S. have now reached nearly 50 percent, and Americans are eager to resume life post-pandemic. However, as flu season approaches and the COVID-19 vaccines' efficacy and longevity have come under question, communities are increasingly concerned about the virus and its Delta and unknown variantsespecially as children return to school this fall. Experts have also speculated this pandemic could become endemic, cycling from season to season. For these reasons, we must continue to stay ahead of the rapidly updating situation and arrive at innovative strategies.

Salvacion's new technology is gaining momentum among the scientific community. The National Cancer Instituteestablished Nanotechnology Characterization Laboratory (NCL) recently selected Salvacion USA Inc. as one of its Assay Cascade awardees for Salvacion's nasal spray, trade name: COVIXYL-V. The announcement appeared in NCL's June 2021 quarterly newsletter, in which Salvacion noted, "COVIXYL-V is intended to reduce SARS-CoV-2 in nasal passages, a main point of entry for the virus in humans. Our unique virus-blocking product, optimized in collaboration with NCL, contains agents which block the virus from attaching to tissue and reducing the viral load in the tissue milieu."

According to NCL's announcement, "Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and pharmacokinetics. The studies are tailored to each individual nanomedicine and are designed to promote the clinical translation of these novel therapies."

Among Nanotechnology Characterization Laboratory's's five awardees, Salvacion is the only one working on a product intended to avert the spread of COVID-19. As an Assay Cascade awardee, NCL commits to funding Salvacion studies free of charge.

Ryan Hwang, a Salvacion spokesman, said, "Our product is preventative and protects nasal passages, halting transmission. Vaccines are developed to protect against COVID-19, but they are not designed to stop transmission. Our strategy is complementary to the effectiveness of vaccines by deterring COVID-19 infection by blocking the transmission."

Salvacion's clinical human trials are currently underway. In vitro and in vivo testing performed thus far suggested that the nasal spray inhibited 99.99 percent of COVID-19. This spray effectively blocked COVID-19 activity in the nasal passages of hamsters, the prime entry points for the virus. One study, performed by an independent BSL-3 laboratory (which, according to Public Health Emergency, is a lab "used to study infectious agents or toxins that may be transmitted through the air and cause potentially lethal infections"), showed that COVID-19 was 99.99 percent inactivated post-spray, with no clinical symptoms experienced by Syrian hamsters from the treatment. No adverse reactions were reported in the hamsters following administration. The data developed in this study showed that the nasal spray product was effective in neutralizing the virus within low concentrations. An additional barrier effect animal study undertaken at an independent laboratory also assessed the COVID-19 blocking effects of the nasal spray. It concluded that the spray created a physical barrier to block the viral particles from taking hold on the surface of the nasal passages. The testing was to prove the mechanism of the nasal spray is capable of blocking the transmission of COVID-19 by creating a physical barrier. The next step is the conducting of a human clinical trial, which is now underway. Salvacion is currently seeking an Emergency Use Authorization (EAU) for its COVIXYL-V nasal spray from the FDA.

This nasal spray is made of ingredients listed as GRAS, or "Generally Recognized As Safe," by the FDA. Unlike other products based on isopropyl alcohol currently being tested, it appears Salvacion's nasal spray could offer a unique blocking system with enhanced effectiveness at a very low concentration. A worldwide patent has been filed for this technology.

"Our nasal spray product may well be the key to moving back to a world that some have thought lost forever to the 'new normalcy,'" said Abdul Gaffar, a Salvacion chemist and recipient of the American Chemistry Society's Heroes of Chemistry Award, who invented this nasal spray.

The contents of this article are for informational purposes only and do not constitute medical advice. It's important to consult with your medical providers and the CDC before making any medical decisions or changes to your health plan, particularly with regard to COVID-19 and its variants.

Read this article:
Complementary Protection May Be at Hand With a COVID-19-Preventing Nasal Spray - Newsweek

Read More...

McMaster University researchers awarded more than $3M in Federal funds for projects – insauga.com

August 17th, 2021 1:53 am

Eleven researchers working out of Hamilton's McMaster University have been awarded almost $3.3 million from the Federal Government for projects deemed to be "on the cutting edge of science andinnovation."

On Wednesday (Aug. 11), Francois-Philippe Champagne, Minister of Innovation, Science and Industry, announced that more than $77 million had been earmarked to support 332 research infrastructure projects at 50 universities acrossCanada.

The funding, made possible through the Canada Foundation for Innovation's (CFI) John R. Evans Leaders Fund (JELF), is expected to help universities attract and retain topresearchers.

"From developing sustainable building materials to creating new laboratories based on Indigenous principles and community engagement, these awards support essential and urgent research," said CFI president and CEO Roseann O'Reilly Runte, in a pressrelease.

"With the necessary spaces and tools, Canada's researchers will play a meaningful role on the global stage and contribute significantly to the quality of life today and for generations tocome."

The more than $3 million going to Mac researchers will help advance their work in health, materials and electrificationresearch.

Projects at Mac that will benefit from the fundinginclude:

Faculty ofEngineering

Bilgen Berker, Electrical and Computer Engineering Project: An Acoustic Noise and Vibration Measurement Facility for Low-noise and High-efficiency Electric Motor DrivesAward:$200,000

Ryan Lewis, Engineering Physics Project: Advanced Epitaxial Nanostructures and Materials LaboratoryAward:$190,584

Zahra Keshavarz-Motamed, Mechanical Engineering Project: Developments of Diagnostic and Predictive Tools and Regulatory Device Testing Machines for Cardiovascular DiseasesAward:$185,000

Maureen Lagos Paredes, Materials Science & Engineering Project: Momentum-resolved EELS Spectroscopy of Beam-sensitive Nanoscale MaterialsAward:$387,788

Faculty of HealthSciences

Lisa Carlesso, Rehabilitation Science Project: Understanding Pain Mechanisms and Management in Neuromusculoskeletal RehabilitationAward:$129,000

Michael McGillion, Nursing Project: Improving Perioperative and canceR Outcomes Through Excellence and appliCation of Virtual Technologies (PROTECT) LabAward:$800,000

Ishac Nazy, Medicine Project: Investigating Novel Mechanisms in Immune-mediated Platelet DisordersAward:$160,000

Michael Surette, Medicine Project: Metagemomics and Genomics of the Microbiome, Infectious Disease and Host ResponseAward:$650,000

Faculty ofScience

Katherine Bujold, Chemistry & Chemical Biology Project: Establishment of Nucleic Acid Nanomedicine Laboratory at McMaster UniversityAward:$75,005

Katrina Choe, Psychology, Neuroscience & Behaviour Project: Neural Mechanisms Linking Autism-risk Genes with Impaired Social BehaviorAward:$400,000

Jeremy Walsh, Kinesiology Project: Integrative Psychophysiology Research LabAward:$100,000

A full list of research projects and funding recipients benefitting from this investment can be found on the CFI website.

Read more:
McMaster University researchers awarded more than $3M in Federal funds for projects - insauga.com

Read More...

MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board – Yahoo Eurosport UK

August 17th, 2021 1:53 am

DGAP-News: MagForce AG / Key word(s): AGM/EGM12.08.2021 / 17:15 The issuer is solely responsible for the content of this announcement.

MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board

Berlin, Germany, and Nevada, USA, August 12, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the results of the 2021 Annual General Meeting (AGM). Due to the COVID-19 pandemic, the meeting was held virtually, as in the previous year. In total, 44.5 percent of the share capital with voting rights was represented.

The Annual General Meeting approved resolution items 2 to 5 as well as 7, 8 and 10 - most of them with a significant majority. Resolution item 6 (Authorized Capital 2021) did not receive the required qualified majority. Norbert Neef, Chairman of the Supervisory Board, informed the Annual General Meeting that he resigns from office effective as of the end of the AGM. Thus, the vote on agenda item 9 was not applicable. Following the suggestion of the supplementary motion of shareholder Avalon Capital One GmbH dated July 29, 2021, Stefan Schtze, attorney and Managing Director of C3 Management GmbH, was elected to the Supervisory Board from the end of this AGM until the end of the AGM that resolves on the ratification of the actions of the members of the Supervisory Board for fiscal year 2021. The Supervisory Board of MagForce AG, which also includes Klemens Hallmann and Aaron Weaver, will hold a constituent meeting shortly to vote on the new chair.

Ben Lipps, CEO of MagForce AG and MagForce USA, Inc.: "From the Management as well as the employees of MagForce, I would like to express my sincere gratitude. Norbert has overseen the Company through its formative years and contributed significantly to the constructive cooperation between the Supervisory Board and the Executive Board that has supported the important decisions in corporate strategy and direction. As a result we have two unique and effective treatment options for glioblastoma and focal intermediate risk prostate cancer. The Management Board wishes Norbert every success in his professional as well as private future. At the same time, we welcome Mr Schtze as new member of the Supervisory Board and look forward to working together to achieve further important milestones for MagForce."

Additional information on the 2021 Annual General Meeting 2021, including detailed voting results, the video address by CEO Ben J. Lipps, as well as the Management presentation on current operational developments, the overview of fiscal year 2020 and outlook for the current year, are available on the Company's website at https://www.magforce.com/en/home/for-press-investors/#general_meetings.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc., is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy system enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: http://www.magforce.comGet to know our Technology: video (You Tube)Stay informed and subscribe to our mailing list

Contact:MagForce AGBarbara von FrankenbergVice President Communications & Investor RelationsT +49-30-308380-77E-Mail: bfrankenberg@magforce.com

Disclaimer

This release may contain forward-looking statements and information which may be identified by terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

12.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Original post:
MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board - Yahoo Eurosport UK

Read More...

Stages of Diabetes: Stages, Symptoms, and Treatments – Healthline

August 17th, 2021 1:52 am

Diabetes is an umbrella term for three primary conditions: type 1 diabetes, type 2 diabetes, and gestational diabetes. According to guidelines established by experts in the field, there are multiple stages of diabetes, each of which are defined by physiological changes within the body.

In this article, well explore the stages of type 1 and type 2 diabetes as defined by diabetes experts, as well as information about long-term diabetes management.

Within the past decade, professional organizations, like the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE), have created guidelines that outline the various stages of diabetes development.

According to the literature on these guidelines, understanding the various stages of diabetes can allow physicians and patients to take a more comprehensive approach to preventive care and disease management.

Below, weve outlined the various stages of beta cell dysfunction, type 1 diabetes, and type 2 diabetes, as established by current experts in the field of diabetes research.

In 2015, the ADA released a joint statement with the JDRF and Endocrine Society outlining the various stages of type 1 diabetes. Using the guideline below, clinicians can more easily diagnose this condition at an earlier stage, even when symptoms might not be present.

Its important to note that type 1 diabetes is an autoimmune disease where the immune system attacks and destroys beta cells in the pancreas, which are responsible for producing insulin.

In this stage, genetic analysis can help identify underlying genotypes that are commonly associated with type 1 diabetes.

According to the research, a specific region on chromosome six called the HLA region is associated with up to 50 percent of the risk for developing this condition. Other factors, like having a sibling or close relative with type 1 diabetes, can also increase disease risk.

In this stage, at least one diabetes-related autoantibody is present in the blood. At this point, these autoantibodies have already begun to attack the beta cells in the pancreas. But blood sugar levels still remain within the normal range, and no symptoms are present.

In this stage, at least two or more diabetes-related autoantibodies are present in the blood. As the beta cells continue to be destroyed by the immune system, a lack of insulin leads to rising blood sugar levels due to glucose intolerance. Although beta cell dysfunction is more serious at this stage, there are still no symptoms yet.

In this stage, theres a significant loss of beta cells due to autoimmunity and symptoms are present, resulting in a type 1 diabetes diagnosis. During this stage, the symptoms of type 1 diabetes may include:

In 2018, the AACE created the dysglycemia-based chronic disease (DBCD) multimorbidity care model. Much like the previous guidelines above from 2015, the DBCD care model helps clinicians take preventative steps to reduce type 2 diabetes complications.

This stage, defined as insulin resistance, is where muscle, fat, and liver cells become resistant to insulin and have trouble bringing glucose into the cell. But the pancreas compensates for this by producing more insulin, which helps keep blood sugar levels within normal range.

In this stage, also known as prediabetes, cells become so insulin resistant that the extra insulin isnt enough to lower blood sugar levels back to normal. In some cases, beta cell dysfunction may also be present. During this stage, blood glucose levels remain higher than normal, but not high enough to be classified as diabetes.

In this stage, blood sugar levels remain abnormally high, leading to a diagnosis of type 2 diabetes. Both insulin resistance and beta cell dysfunction can lead to high blood sugar levels in type 2 diabetes. Without treatment, these elevated levels can cause long-term damage to the body.

In this stage, vascular complications can occur as a result of high blood sugar. As blood sugar levels remain high, damage can occur within the vascular system, leading to potential complications like:

While end-stage diabetes isnt a commonly used term, diabetes can lead to whats known as end-stage diabetic complications, or advanced complications. In people with diabetes, advanced complications, like end-stage renal disease, occur after many years of living with diabetes.

A study from 2019 found that microvascular complications from diabetes, like nephropathy, increase risk for cardiovascular events and death in people with type 1.

While theres no cure for diabetes, it can be managed through the appropriate treatment, which may include medications, dietary changes, and lifestyle interventions.

Although it can feel overwhelming to manage a chronic health condition like diabetes, your healthcare team is there to help you create a diabetes treatment plan that works best for you.

If youre concerned about managing your diabetes, the first step is to reach out to your doctor or care team to create a diabetes treatment plan. Depending on your diagnosis and personal needs, your treatment plan may include reaching out to:

According to experts in the field of diabetes research, diabetes staging plays an important role in the prevention, diagnosis, and treatment of diabetes. Understanding the various stages of both type 1 and type 2 diabetes allows physicians and patients to see the progression of the disease so that treatment and long-term management can be improved.

If youve been diagnosed with diabetes, its important to stay educated about your condition so that you can more easily manage it in the long-term.

Go here to see the original:
Stages of Diabetes: Stages, Symptoms, and Treatments - Healthline

Read More...

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism – Yahoo Finance

August 17th, 2021 1:52 am

NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original article titled "Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes mellitus - A randomized placebo-controlled trial" authored by Dr. Roy Eldor, Dr. Joel Neutel, Kenneth Homer and Oramed's Chief Scientific Officer, Dr. Miriam Kidron.

Oramed Pharmaceuticals Logo

The article presents the results of a trial that assessed the safety and efficacy of Oramed's lead drug candidate ORMD-0801 in type 2 diabetes (T2DM). The trial met its primary endpoint and found that in patients with T2DM, bedtime ORMD-0801 curbed increases in night-time glycemia, 24-hour glycemia, and HbA1c without increasing the risk of hypoglycemia or safety events as compared to the control arm.

"I'm proud and excited that this paper, exploring the interesting and important results of Oramed's Phase 2 study of oral insulin has been published by Diabetes, Obesity and Metabolism," said Roy Eldor, M.D. Ph.D., Director, Diabetes Unit, Institute of Endocrinology, Metabolism & Hypertension, Tel-Aviv Sourasky Medical Center, and a member of Oramed's Scientific Advisory Board.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule.

Story continues

For more information, please visit http://www.oramed.com.

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential efficacy and safety of ORMD-0801, the ability of Oramed to transform the treatment of diabetes and the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Logo - https://mma.prnewswire.com/media/647544/Oramed_Pharmaceuticals_Logo.jpg

Company ContactJosh Hexter +1-844-9-ORAMEDjosh@oramed.com

Cision

View original content:https://www.prnewswire.com/news-releases/oramed-announces-publication-of-oral-insulin-study-in-peer-reviewed-journal-diabetes-obesity-and-metabolism-301355754.html

SOURCE Oramed Pharmaceuticals Inc.

Read more from the original source:
Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism - Yahoo Finance

Read More...

Diabetes cases soar by 60% in just five years in under 25s know the signs… – The Sun

August 17th, 2021 1:52 am

CASES of diabetes are on the rise in young people, driven by the obesity crisis.

Being aware of the signs could prevent serious complications from the disease if a child or young person gets an early diagnosis.

1

Diabetes is a serious condition which needs lifelong management.

Unfortunately, type 2 diabetes - which accounts for 90 per cent of all cases - is accelerating as a result of factors including obesity.

More often than not, the condition is triggered by poor lifestyle habits like eating too much unhealthy food or not exercising.

The effects are now being seen in children, some younger than 12 years old, who previously were more likely to get type 1 diabetes, which is genetic.

New figures show a 60 per cent increase in under 25s with type 2 diabetes being treated at paediatric diabetes units in England and Wales over five years.

There were 866 under-25s who got treatment in 2019/20 compared with the 322 in 2014/15, according to the stats published by Royal College of Paediatrics and Child Health.

Just over 84 per cent of the patients were registered as obese, broadly in line with previous years.

Nikki Joule, policy manager at Diabetes UK, said: Type 2 diabetes is no longer just a condition found in older people; it can affect any age.

We also know that type 2 diabetes is likely to have more severe and acute consequences, if they develop it as children especially if they do not have access to the right specialist treatment and support.

Childhood obesity is the main driver behind the rise in cases."

It comes after a new report revealed almost 1,600 children under 19 in England have type 2 diabetes.

Diabetes UK warned that the NHS Digital data on August 12 confirms a recent growing trend of serious health conditions related to obesity that are becoming more prevalent in a younger demographic than ever before.

It highlighted nearly a third of children aged two to 15 years old were overweight or obese.

Chief executive Chris Askew said the figures were a worrying wake-up call.

NHS Digital data shows that people who get diabetes under 40 years old are more likely to:

Symptoms of diabetes can go completely missed because people think they are caused by something else.

Or their symptoms dont necessarily make them feel unwell, so they are not even acknowledged.

The most common early signs of type 2 diabetes are frequent urination, extreme thirst, and persistent hunger.

You should visit your GP if you are:

There are other symptoms that may alert you to this disease.

These include:

In children

Dan Howarth, Head of Care at Diabetes UK, said: The symptoms of diabetes needing the toilet more often than usual, feeling more tired or thirsty than normal, and unexplained weight loss are the same for people of all ages, and with all types of diabetes.

"Symptoms of type 1 diabetes develop very quickly, whereas type 2 diabetes symptoms come on more slowly.

"In children and young people with type 2 diabetes, symptoms may be less noticeable, with cases often going undetected."

But more specific problems to look out for are:

If your child is very overweight, the NHS says there are things you can to help them get to a healthy weight.

This includes upping exercise, keeping portions to child-sized, and eating healthier foods.

Exercise doesnt need to be any more than playing it, riding a bike, swimming or using a playground, so long as they are happy and moving.

All children need about 60 minutes of physical activity a day for good health, but it doesn't need to be all at once, the NHS says.

Food wise, children should avoid eating too much of the same things that cause weight gain in adults - sweets, chocolate, crisps and cakes.

Its important that as a parent, you also act as a good role model and try and get the whole family involved, so it doesnt feel like your child is targeted.

It can be a scary time if your child is diagnosed with diabetes, but doctors will be there to support you.

Your child will get a treatment plan that you as a parent will be involved with administering - including insulin injections.

You will also have to keep a close eye on your child's glucose levels to make sure they dont become dangerously low or high.

On top of this, children with diabetes will need to eat a healthy diet and exercise is considered incredibly important, Diabetes UK says.

Dan, Head of Care, said: Some people with type 2 diabetes can put their diabetes into remission through a combination of weight loss and lifestyle changes.

"While research into remission and young people with type 2 is ongoing, we know that by making lifestyle changes such as keeping physically active and eating healthily, families and young people with type 2 diabetes can increase their chances of remission, reduce their risk of diabetes-related complications risk and improve their overall health.

For more information about diabetes, visit diabetes.org.uk

Read more from the original source:
Diabetes cases soar by 60% in just five years in under 25s know the signs... - The Sun

Read More...

Diabetes startup brews up $11M after ‘serendipitous spill’ led to creation of new CGM tech – FierceBiotech

August 17th, 2021 1:52 am

Many of the most groundbreaking discoveries have happened accidentally: The microwave oven, for one, was developed after physicist Percy Spencer noticed a chocolate bar in his pocket had melted while he was experimenting with a magnetron. Penicillin was born out of the bacteria-killing mold that grew on a petri dish while biologist Alexander Fleming was on vacation.

Perhaps aiming to join their ranks is Israeli startup Hagar, with itsGWave technology that measures blood sugar levels using noninvasive radio waves rather than an implanted sensor or repeated fingersticks.

According to Hagar lore, the technology came about after Geri Waintraub, the companys co-founder and chief technology officer, accidentally spilled a cup of tea on a radio frequency device during a separate research project and concluded that the ensuing reaction was caused by the sugar in his tea. Thus, GWave was born.

RELATED: Dexcom gets FDA go-ahead to pair diabetes data with Garmin, Livongo and more through 3rd-party APIs

The first generation of the GWave sensor is a device about a third the size of a standard smartphone,inserted into a ceramic bracelet. It uses Bluetooth to transmit its glucose readings to an accompanyingmobile app that tracks readings and alerts users to fluctuations in their blood sugar levels.

While radio waves are a form of electromagnetic radiation,GWave produces significantly less amounts than a smartphone, according to Hagar.

A proof-of-concept study found the company's radio frequency technology was able to continuously measure glucose levels with at least 90% accuracy, compared to the estimated 70% rate for traditional continuous glucose monitors.

According to the company, that difference stems from the fact that Hagars system directly measures glucose in the blood in real time. Other CGMs may use a sensor implanted under the skin to take measurements from the interstitial fluid between cells and may often have to be calibrated throughout the day with routine fingerstick blood tests.

RELATED: One Drop poaches Sanofi's head of diabetes innovation to bring CGM biosensor to market

Backed by those promising results, and with Hagar now planning to launch clinical trials to pursue FDA approval of the GWave system, the company has raised $11.7 million in series B funding.

The financing was led by Columbia Pacific and comes shortly after Hagar closed its series A, which brought in$4.4 million just last March. Those back-to-back funding rounds bring the companys lifetime funding to just over $17 million.

With 8.3% of the U.S. population living with diabetes today, that number is projected to rise to one in three adults by 2050. Finding a way to monitor glucose levels in the bloodcontinuously, painlessly and easilyis life-changing for those living with diabetes, and we are thrilled that our partners at Columbia Pacific are helping us in this journey, said CEO Guy Zur.

Next up, along with plotting out clinical trials of its technology, Hagar will continue developing the second-generation GWave device. In that iteration, the sensor will be embedded into a smartwatch that will be able to display the readings collected by the GWave mobile app.

View original post here:
Diabetes startup brews up $11M after 'serendipitous spill' led to creation of new CGM tech - FierceBiotech

Read More...

Diabetes Canada and LIFT session team up to support Canadians living with diabetes – Canada NewsWire

August 17th, 2021 1:52 am

MONTREAL, Aug. 16, 2021 /CNW Telbec/ -LIFT session, a leading Canadian digital fitness and wellness platform, has entered into a partnership with Diabetes Canada to bolster fundraising for their annual event Lace Up to End Diabetes. Lace Up to End Diabetes, presented by GMS Health & Travel Insurance, is a virtual walk, run, dance your way to 10K campaign taking place from Sept 1-30, 2021. This year the event also includes a 100KM fitness challenge in support of the 100th anniversary of the discovery of insulin.

The partnership with LIFT session will help drive this fundraising initiative and encourage more people to engage in their physical and mental wellbeing. By reaching certain fundraising goals, participants will get exclusive access to LIFT session's best in class employee wellness solution, including live coach chat, AI based workouts and 3 live online group training sessions.

Furthermore, LIFT session and Diabetes Canada plan on exploring future opportunities to build on their partnership through innovative digital wellness fundraising strategies.

"Diabetes Canada is excited to offer this digital fitness opportunity to Lace Up participants" Nicole Holder-Dulson, Regional Director, Ontario. "Fitness and wellness have historically been a powerful tool in fundraising, and a digital offering makes fundraising borderless. LIFT was the ideal partner, as the platform ensures users receive curated workouts specific to their goals and fitness levels, with live support from wellness experts.

"Our mission at LIFT session has always been to increase the overall health of our society." saysRaffi Tchakmakjian, CEO of LIFT session. "Diabetes is a disease that affects us all and this partnership is just the first step in our efforts to help end diabetes. It's an honour for us to help power a quintessential organization like Diabetes Canada in their ambitions to expand their fundraising reach through digital fitness."

To learn more about the service, please visit Lace-up's website at:Lace-up by Diabetes Canada.

ABOUT DIABETES CANADADiabetes Canadais the nation's most trusted provider of diabetes education, research, resources, and services. We've helped millions of Canadians affected by diabetes understand it, manage it, and combat complications since 1953.

ABOUT LIFT SESSIONLIFT session's goal is to make top fitness coaching and sessions accessible to anyone, from any location and on-demand. By offering services through wellness providers and businesses, LIFT session offers its online fitness platform to millions of customers globally.

LIFT session's customers are invited to participate in automated AI based workout sessions, live group and one-on-one online training sessions, either on their own or through highly engaging LIFT corporate challenges. The platform offers a wide range of fitness classes from high intensity interval training to Pilates, yoga, dynamic stretching and mobility. LIFT session helps members to achieve their personal goal whether they are training for a competition, preparing for an event, looking to shed a few pounds, or just looking to build a healthy lifestyle. Follow LIFT session on Instagram and Facebook @liftsession.

SOURCE LIFT Digital Inc.

For further information: David Sciacca, [emailprotected], (514) 994-8058

liftsession.com

See the rest here:
Diabetes Canada and LIFT session team up to support Canadians living with diabetes - Canada NewsWire

Read More...

Hallberg given Sagamore of the Wabash for work in diabetes research – Journal & Courier

August 17th, 2021 1:52 am

LAFAYETTE, Ind. Dr. Sarah Hallberg, the medical director at Virta Health, was recently awarded the Sagamore of the Wabash award for her work in diabetes research.

The Sagamore of the Wabash first started in 1946 with then-Indiana Gov. Ralph Gates. Gates was on his way to a conference of Kentucky, Indiana and Ohio officials when he learned that the then-Kentucky governor, Simeon S. Willis,planned to award gates the Kentucky Colonel, the state's highest honor.

Not to be outdone by Kentucky, Gates named Willis the first recipient of the Sagamore of the Wabash. Since then, thousandsof people have received this honor, including David Letterman, Muhammed Ali, and now, Dr. Hallberg.

According to its description, TheSagamore of the Wabash is the "highest honor, which the governor of Indiana bestows. It is a personal tribute usually given to those who have rendered a distinguished service to the state or to the governor."

"Among these who have received Sagamores have been astronauts, presidents, ambassadors, artists, musicians, politicians, and ordinary citizens who have contributed greatly to our Hoosier heritage."

Wabash Township: Trustee proposes increasing her salary in 2022

There is no official record of how many have been presented with this honor, as each governor has kept their choicesdocumented using different methods.

"I was just floored," Hallberg said about she show felt when she won the award. "I'm so lucky to have had this career where I can really help people improve their lives, and be a real patient advocate."

Before joining Virta Health, Hallberg worked at IU Health Arnett Hospital where she founded the Supervised Weight Loss Program.This clinic served as the host for Virta's clinical trials.

"What I came across was carbohydrate restriction," Hallberg said, "and we opened the clinic as a carbohydrate-restricted clinic. That was the nutrition intervention that we were using. What we were seeing in patients was just remarkable. When we were putting them on a therapeutic, carbohydrate-restrictive diet, their diabetes was going away."

These clinics took place about a decade ago, according to Hallberg, and up until thatpoint, Type 2 Diabetes was seen as a chronic and progressive disease. Seeing the effects a carb-restricted diet has on patients motivated Hallberg to expand her research to beyond her clinic in central Indiana.

2020 U.S. Census: Tippecanoe County population increased, more diverse

Dr. Stephen D. Phinney, the chief innovation officer and co-founder of Virta Health, and Hallberg have worked and continue to work on a number of published papers together to help get the news of reversible diabetes through carb-restriction out there.

"The biggest thing is that this study, in central Indiana, changed the American Diabetes Association guidelines," Hallberg said. "We did this research that impacted the guidelines that haveimpacted so many Americans. And that happened here in central Indiana."

Four years ago, Hallberg was diagnosed with advanced lung cancer. She explained howher diagnosis and her work experience being a patient advocate both affected her.

"Being a patient advocate for so long and just wantingto empower and teach them (the patients) with the science," Hallberg said, "really came into play for me four years ago when I became a patient myself. So all the advocacy I've done for my patients, I was really fortunate in that I could turn that into being an advocate for myself with an advanced cancer diagnosis."

Margaret Troupis a reporter for the Journal & Courier. Email herat mtroup@jconline.com and follow heron Twitter@MargaretTroup2

The rest is here:
Hallberg given Sagamore of the Wabash for work in diabetes research - Journal & Courier

Read More...

New Stem cell conveying hydrogel could assist the heart with recuperating myocardial ischemia – Microbioz India

August 17th, 2021 1:52 am

When blood vessels that feed the heart become blocked, damage to the heart muscle can occur and this can affect cardiac function. By stimulating the formation of new blood vessels, a new stem-cell-carrying gel helps mice overcome this condition called myocardial Infarction. The stem cell delivery system was developed by scientists from Kansai University, Japan. It is published in Science and Technology of Advanced Materials.

The hydrogel acts like a scaffold to hold the stem cells in place at injection site and keep them alive longer. The stem cells release cytokines, which stimulate the formation blood vessels and help the heart to recover. The gel is biodegradable so that it eventually dissolves and can be discarded by the body. Image credit: Kansai University

In their application, the team used stem cells from fat tissue. These stem cells, also known as adipose derived stem cells, have been used in the treatment of damaged cardiac tissue due to reduced blood flow. This is called myocardial Ischemia. Once injected into damaged tissue, the stem cells are supposed to release stimulants that can help regenerate blood vessels. However, they are not able to be retained in the tissue or survive long enough. Scientists have also found that injecting biodegradable hydrogels, which are cell-free, into damaged heart tissue can help partial recovery.

They first created hydrogels that could hold stem cells in place longer at the site where there is tissue damage. They are best used at room temperature. This allows you to easily mix the stem cells. The solution reacts with the body to heat and transforms into a gel when it is injected into the organ.

One hydrogel was particularly good at keeping its gel state. It was made from a mixture of molecules called tri-PCG with acrolyl group attached. The tri-PCG-acryl mixture was then combined with a polythiol derivative.

The team also added stem cells from adipose tissue to the hydrogel. They then observed how long they lived in petri dishes as well as the production of different genes and substances.

The stem cells were able to survive in our injectable hydrogel and released molecules that stimulate blood vessel formation, improving heart function and making it effective for treatment of ischemic heart.

Yuichi Ohya, Bioengineer, Kansai University

After confirming safety, the team plans to next test the therapy on larger animals and then conduct clinical trials in humans. They plan to use their injectable hydrogel for immune cells to treat cancer and in vaccines against viral infections.

Source:

Journal reference:

Yoshizaki, Y.,et al.(2021) Cellular therapy for myocardial ischemia using a temperature-responsive biodegradable injectable polymer system with adipose-derived stem cells.Science and Technology of Advanced Materials.doi.org/10.1080/14686996.2021.1938212.

Read the original here:
New Stem cell conveying hydrogel could assist the heart with recuperating myocardial ischemia - Microbioz India

Read More...

Participants Diagnosis Halts Gene Therapy Clinical Trial – The Scientist

August 17th, 2021 1:52 am

Aclinical trial testing a novel gene therapy for a rare neurological disease has been put on hold after one of the participants in a Phase 3 trial developed a bone marrow disorder that can lead to cancer. The pause, announced Monday by the trials sponsor, bluebird bio, and mandated by the US Food and Drug Administration (FDA), was taken out of an abundance of caution, the companys president of rare genetic diseases, Andrew Obenshain, said in a recent quarterly call.

The therapy targets cerebral adrenoleukodystrophy, which is caused by a mutation in the gene for an enzyme called adrenoleukodystrophy protein (ALDP) that breaks down fats. The mutation causes fat to build up in the brain, where it breaks down the insulating myelin that allows neurons to communicate with one another. Because the gene is on the X chromosome, women typically have a least one good copy, so the disease primarily strikes men. Left untreated, it causes damage to hearing, vision, cognition, and coordination. It is often fatal.

Bluebirds gene therapy uses an engineered lentivirus to correct the mutation associated with the disease. Lentiviruses belong to the same family as HIVretrovirusesand have been widely used in gene therapies and other medical applications for many years. While other virus-based platforms using retroviruses had previously been linked to cancer among patients, it is only recently that a lentivirus has been implicated in such an outcome: in February of this year, bluebird bio paused another trial, one for a blood disorder, after two patients developed leukemia-like cancer, Sciencereports, although it was later determined that the virus was likely not the cause, and the trial resumed.

Most in the field were hoping that we would not see such an event with lentiviral vectors, Harry Malech, a gene therapy researcher at the National Institutes of Health, tells Science, adding, I dont think anybodys been . . . saying this couldnt happen.

The cerebral adrenoleukodystrophy therapy involves taking samples of a patients bone marrow and treating the stem cells therein with the modified virus that contains a corrected copy of the gene that encodes ALDP. After a round of chemotherapy to reduce the persons bone marrow cells, the treated cells are infused back into the patient. Thereafter, the patients stem cells produce healthy blood cells with a functional copy of the gene for ALDP. The therapy entered the market in Europe last month following a previous safety and efficacy trial that included 32 patients. A second trial, the one that has now been paused, was set to finish in 2024.

Speaking on the call, bluebird bios Chief Scientific Officer Philip Gregory said that one patient in the second trial developed myelodysplastic syndrome (MDS), a blood disorder that sometimes leads to leukemia, and another two had abnormal bone marrow cells that could progress to MDS. When scientists examined their cells, they found lentiviral DNA inserted at a site in the genome that has previously been linked to MDS in retrovirus-based therapies, suggesting that the virus may have caused the changes.

Specifically, Gregory said the issue is likely caused by the virus promoter, the DNA sequence that turns on the therapeutic copy of the gene. To ensure the gene produces enough ALDP in the brain to be an effective treatment, the researchers needed a strong promoter, but as a consequence, the promoter had off-target effects, turning on other genes in the area around the mutation, including cancer genes, Gregory speculated.

Donald Kohn, a gene therapy researcher at the University of California, Los Angeles, who helped design the viral vector, tells Sciencethat in the time since bluebird bio first began developing the therapy, researchers have identified other promoters that might be able to do the job with a lower risk of causing cancer. He adds that this particular incident shouldnt preclude scientists from pursuing other lentivirus treatments, as the issue seems to come down to design, and Kohn doesnt know of any other lentivirus therapies that use the same type of promoter.

Panam Malik, a hematologist at Cincinnati Childrens Hospital who was not involved in the work, similarly tells Science that virus-based platforms should be highlighted for the good they have done. This is a severe adverse event, she says, but adds, we should never lose sight of the fact that so many patients . . . have been helped. Despite this rare incident, the findings could help scientists and researchers design safer and better vectors for the future.

Continued here:
Participants Diagnosis Halts Gene Therapy Clinical Trial - The Scientist

Read More...

The Involuted Palate, or the Savage Crinkle of Future Snacks – lareviewofbooks

August 17th, 2021 1:52 am

AUGUST 11, 2021

FOR THE ARCHITECTURAL HISTORIAN and critic Reyner Banham, the bag of potato chips (or crisps as he, an Englishman, put it) was a remarkable technological innovation. But it was an emotional object rather than a practical one. The sound of the bag crinkling and tearing as you ripped it open and consumed every greasy chip and then the shards at the bottom, expressed the temper of the late 20th century: Its the first and most familiar of Total-Destructo products and probably sublimates more aggression per annum than any quantity of dramaturgical catharsis, Banham wrote in his short essay The Crisp at the Crossroads (1970). Banham speculated about the possibilities for flavored chips: not just cheese-and-onion or barbecued bacon, but toad in the hole, crme de menthe, and more, all of them flavor stations along the expanding snacking frontier. But flavor seemed to interest him less than form. The relationship between chip and bag seemed to him almost vernacular: the bag of chips was like some survivor from a lost golden age of peasant technologies that have matured long in the wood and hand: the oar, the axe, the rolling pin. The chip glows golden when you hold it up to the light but it is unlike the oar, axe, or rolling pin, because its vernacular quality stems from the way it pairs with its packaging, the proper use of both involving a crinkling burst. The chip is an impractical food if the task is to get the most nutrition possible out of the potato; but if the task is to pleasurably wreck something, then the chip-and-bag is very good design indeed.

Fifty years later, the chip retains its basic shape, although some chips are now chili mango flavored. And the world of snacking R-and-D has not run out of steam. Entrepreneurs, working to transform food through technology, seem to promise new innovations every day, not all of them intended as mere snacks. There are pea protein puffs, and new kinds of plant-based burgers, and bunches of kale leaves grown hydroponically in vertical farms. The most ambitious of them all, the dream of growing meat in labs, hovers at the horizon, gaining headline coverage as companies promise to produce it soon but cultured meat never quite arrives in the supermarkets. The entrepreneurs call all these things innovations. But what if the best metaphor for describing new food-tech products was not innovation but involution? That latter term stems from the Latin involutio and carries the meaning of curling inwards (as a chip curls) but has more common meanings, which the OED provides: the state of being complicated; the shrinkage of old or inactive tissue in the body; a mathematical function, transformation, or operator that is equal to its inverse, or in other words, that continues to be itself when applied to itself. This should sound counterintuitive, for we are used to thinking of technological changes as introducing novelty into a system, perhaps changing that system fundamentally, rather than causing it to curl in on itself. In any case, involution may seem like a lofty term to apply to crunchy protein bars made with cricket flour, ersatz meat made by extruding pea protein, or powdered algae, but I will argue for the terms explanatory power bite by bite.

In his 1936 essay Loose Ends of a Theory on the Individual Pattern and Involution in Primitive Society, the anthropologist Alexander A. Goldenweiser put involution on anthropologys map. While meditating on the relationship between individual expression and cultural patterns, Goldenweiser used involution to describe an enduring condition in which patterns both in the sense of physical symbols but also forms of social behavior run through every aspect of a human communitys life, providing both a fabric of meaning and a limiting, even restrictive force. In primitive societies, Goldenweiser wrote, pattern is particularly conspicuous in rituals and the forms of religious objects, where the tenacity of pattern is enhanced by social inertia or a sacred halo. Pattern limits development, and Goldenweiser seemed to imply that an intimate relation with pattern was part of what kept primitive societies primitive. It inhibited the technical, social, and intellectual developments that could eventually lead to modernization.

But patterns also set limits in a more positive sense, as a canvas edge or a frame establishes the boundary for a painting. Thus Goldenweiser characterized the traditional art of the Maori, in which simple units of design recombine in multiple ways within a delimited space: The inevitable result is progressive complication, variety within uniformity, virtuosity within monotony. This, too, is involution. Involution wasnt limited to primitive contexts; Goldenweiser also found its inward curling in late Gothic art, whose structures and component parts may be fixed but still express play and creativity in elaborations on basic themes. But Goldenweiser saw involutions limits as ultimately negative:

Expansive creativeness having dried up at the source, a special kind of virtuosity takes its place, a sort of technical hairsplitting. No longer capable of genuine procreation, art here, like a seedless orange, breeds within itself, crowding its inner structure with the pale specters of unborn generations.

Like a seedless orange? Or like a protein bar made with cricket flour, its basic design already set by the architects of snacking, but filled with the bodies of insects? Crunch! Complexity. Crunch! Sameness.

Larissa Zimberoff, in her admirably skeptical book Technically Food: Inside Silicon Valleys Mission to Change What We Eat, describes the contemporary food-tech nexus, surveying a wide range of startup companies, mostly based in the San Francisco Bay Area. She interviews dozens of entrepreneurs, encountering them at tech conferences or in the warehouses and labs where they try to grow the future. She hears their pitches and then examines those pitches to see if they survive close scrutiny. Many of Zimberoffs entrepreneurs claim that their products will replace existing foods that are environmentally unsustainable or cruel to nonhuman animals. Their mission, then, is one of supersession. What if you could eliminate animal agriculture, with its massive environmental footprint and relatively inefficient transformation of plants into animal protein? Sensitive to concerns about the environment, and about animal cruelty, Zimberoff keeps human health at the books center: are these new foods really going to be better for us, especially given that so many of them are ultra-processed, a category linked to bad health outcomes? How about the well-known plant-based Impossible and Beyond Meat burgers? They are far more fatty and caloric than, say, a meal of chickpeas. Coconut oil, a key ingredient used in most plant-based meat, is about 90 percent saturated fat. Memorably, Zimberoff compares the creation of these burgers to fabricating a Slim Jim, which is made from chicken scraps through the same technique, extrusion. Are these different products? Yes. Are they similarly made? Yes. Zimberoffs book is marbled with detail, and performs a useful analytic service for readers trying to understand new tech foods: while many novel food companies claim to break out of the paradigms set by Big Food (those huge international companies that fill the central aisles of grocery stores with processed stuff ), Zimberoff shows that many of their founders hope to sell ingredients to Big Food, and use processing techniques that Big Food perfected or they may plan to sell the whole company to Big Food, lock, stock, and bioreactors.

As I followed Zimberoffs journey from one warehouse-based company to another, from algae to fungi, from pea protein to vegan milk and eggs, from plant-based burgers to vertical farming, and all the way to cultured meat, I found myself thinking back to Goldenweisers essay. How can we tell if a given novel food technology represents innovation, the change that changes everything, or if it represents involution, a change that ultimately changes nothing within enduring cultural, economic, and social patterns? Disclosure: I appear briefly in Technically Food as an expert on cultured meat, the subject of my own 2019 book, Meat Planet: Artificial Flesh and the Future of Food; Zimberoff spoke with me several times during her research. I spent years conducting fieldwork with tissue engineers and other scientists, as well as with entrepreneurs and futures consultants, who hope to grow animal muscle and fat, consumable as meat, from biopsies of cells, obviating the need for industrial animal agriculture. Hypothetically, cultured meat would require vastly fewer natural resources, and cause no cruelty to animals at all. We could visit a pig on a farm, eat meat grown from a biopsy of its cells, and then play with that same pig. If this effort succeeds, I believe it will constitute the largest and fastest shift in human subsistence strategies in history. Watch your step. That initial if is a doozy.

Innovation or involution? Form is the first clue. The wonder foods in Zimberoffs book mostly imitate familiar foods like chips, puffs, bars, shakes, and burgers. They may be made of new materials, but those materials do not dictate their shape. A plant-based sausage, with its arbitrary relationship between form and material, is in fact a skeuomorph, a Greek term which more or less means vessel-form. Its shape is like a container that used to be filled with other stuff, stuff that dictated the original form of the container consider those lintels of ancient Greek temples that rendered, in stone, the ends of protruding wood beams. Where pig intestines once gave sausage its shape, cultural expectation now dictates a cylinder, tapered where the traditional length of intestine was tied off at the ends. The compass in a smartphone doesnt work the way a magnetized needle does, but the digital representation of the compass on the phones screen is familiar, expected. The shapes of meat surrogate products, whether they are based on plant or animal cells, now come not from the bodies of animals, nor from the inspiration of corporate sculptors (should such a professional category exist outside my fantasy life), but from the imagined desires of consumers: burgers, sausages, chicken nuggets. Formally speaking, then, there is something involuted about the new food products Zimberoff documents. Apparently, when you ask consumers to think of plants as meat, you first must make the plants meat-shaped. And in the process you realize that meat, in our era of industrial mass-produced cheapness, has taken on arbitrary shapes. Nuggets do not appear on the bodies of chickens, at least not healthy ones.

Theres a great deal of repetition at the food-tech nexus. Soylent, the well-known meal replacement shake, closely resembles SlimFast, the diet drink targeted at women from 1977 onward. When the company Hampton Creek, which now calls itself Eat Just, released a vegan mayonnaise product, it was nearly identical to another 1977 product (odd coincidence) called Vegenaise, resembling it so closely that the creators of Vegenaise were shocked. Some of this repetition is probably conscious; Follow Your Heart, the maker of Vegenaise, has been around for a long time. And some of it may stem from entrepreneurs simply following a common pattern of thinking, according to which the problem with our food system is not our eating habits, but the nature of our food itself. Why not keep mayonnaise but make it vegan? Why not keep drinking milk, or eating ice cream, but make it from milk proteins we grow in a lab? What if we could get our artificial dyes, not to mention our protein powder, from algae? Some companies are making mycelium steaks, working with the fungus, related to mushrooms, that looks a bit like an underground network of threads. If you abstracted mycelium from the earth in which it lives, it might look like a mystical fairy network. From the standpoint of the anthropology of food, it is fascinating to notice that entrepreneurs first instinct was not to work with the natural form of those mycelium threads, to see what kind of food product might follow from that form, but instead to ask if mycelium could become an ingredient in something perceived as marketable. Throughout my research into cultured meat, I was bemused by the striking combination of inventiveness in the lab, as scientists adapted tissue culture techniques, widely used in medical research, to food production and the topological sameness of the burgers, hot dogs, and chicken nuggets that entrepreneurs hoped to produce. Theres a lot of copycat innovation not a lot of real innovation, says one of Zimberoffs interviewees, the CEO of a fungi-based meat company. Again, I recall Goldenweiser: The inevitable result is progressive complication, variety within uniformity, virtuosity within monotony.

Does all this count as involution? Taking stock, we are looking at an intense mimetic tendency, with food makers producing products that resemble each other, even if they differ in surprising ways in their raw ingredients or how they are processed. We have consistency within the pattern of seeking ever more clever ways to process foods in pursuit of value (because the greatest profit lies, as the work of food scholar Marion Nestle has shown, in processed foods). We have entrepreneurs seeking to change our products rather than the way we consume them. We have sector-wide ideological agreement that our food systems problems must be essentially technical, perhaps because technical solutions are the ones we can imagine using (and getting funded). In Meat Planet, I argue that this represents a form of imaginative closure, in which the economic, social, and ultimately political character of our food system gets obscured, because of the appeal of technological tools. This does not mean that technologies wont change our food system (indeed, if cultured meat works, it really could change everything) but that what makes the whole system of food-tech entrepreneurship work, imaginatively speaking, is the idea that technology, plus the workings of the consumer market, can provide all the change human civilization needs. Another way to express this imaginative closure may be in terms of involution. I must consider a straightforward objection to such claims. Goldenweiser thought that involution means that pattern checks creativity and development. But much of the work done at the food-tech nexus is mightily creative, and sometimes involves new ways of solving problems having to do with texture and flavor. Innovation surely describes this. Snackland is not bereft of ideas. A fair view of involution and innovation at the food-tech nexus might be that the nexus displays both traits at once. And yet involution always seems to win, because the creativity and inventiveness of food scientists takes place within economic systems they cannot contest, and usually do not want to. The nature of involution, for Goldenweiser, is that we cannot see outside a pattern, and here the salient pattern is a model of production, consumption, and value seeking that we often shorthand to capitalism.

In his 2006 book Meals to Come: A History of the Future of Food, historian Warren Belasco chronicles a set of long-running debates about the future of food, debates that have run through universities, think tanks, and into the public realm of journalism. A few major schools of thought have dominated those debates. There are Malthusians, who believe that increases in agricultural yields (due to technological progress, perhaps) tend to fall behind increases in population, because the former rises arithmetically and the latter geometrically. This means that the poorest members of any society will be exposed to malnutrition and that we have compelling reasons to impose artificial limits on population growth. There are Cornucopians who believe that technological progress will in fact outpace population growth, producing enough for all, possibly without limit. Then there is a third group, more equality-minded, who believe that the solution to problems in the food system is not a matter of managing supply and demand, but achieving more equal distribution of what we produce through better governance. The debate between the three positions began in the late 18th century, and while Malthusianism has always been influential it helped shape the food policy of the British Empire, since Thomas Robert Malthus himself taught at the school run by the British East India Company it is in Cornucopianisms belly that we effectively live and work today, getting slowly ceviched by its digestive juices. Those who work at the food-tech nexus are trying to keep Cornucopianism alive (although they may not identify with that term at all) in a new millennium, as the pressures of environmental crisis loom large. Cornucopians dream of a world with nothing but upside we save the environment and our market economies, predicated on growth, all at once. I was reminded of this when one of the companies trying to make cultured meat, previously called Memphis Meats (but based in Berkeley) rebranded as UPSIDE Foods. If you uncase a Pringles Wavy Potato Crisp and examine it from the right angle, it looks like a smiley face.

Cultured meat displays involution and innovation at once. Its researchers display great creativity in their technical efforts to take animal muscle stem cells, as well as fat cells, and induce them to grow in vitro, adapting a technique called tissue culture, which itself dates back to the early 20th century, to food production. They play with scaffolds on which animal cells can grow; they search for ideal growth media to feed their cells; they ask if it might be advantageous to combine the cells of different species in a single piece of meat, because one speciess cell line seems to produce better fat, the other better muscle, under laboratory conditions. And yet this work unfolds within a set of assumptions about the shape of meat, and appetites for meat, not to mention the assumptions that the combined powers of technology and the market will solve our human problems. In 2019, a chemical engineer named Dave Humbird was hired to conduct a feasibility study for cultured meat. I spoke with Humbird as he pursued his research and wrote his report. While other researchers have conducted feasibility studies and lifecycle analyses for cultured meat, Humbirds was the first by a scientist with no material or ideological investment in the proposition of cultured meat. His conclusions were not encouraging for anyone who hopes that cultured meat will work at scale, its costs eventually decreasing enough that it undercuts and supersedes conventional meat. Humbird found challenges both economic and technical some of the latter derived from the kinds of physical stresses on cells grown in very large bioreactors, and some of the former derived from the costs of raw ingredients. Both strongly suggest that cultured meat might never scale effectively. But I was also intrigued by Humbirds observation, relayed to me conversationally, that very few people involved with the nascent cultured meat industry either as entrepreneurs or as investors contacted him about his study, or spoke openly about his findings, even to challenge them. This fit a pattern I had long observed during my fieldwork, namely that despite the considerable hype around cultured meat, there is relatively little balanced public discussion of its technical feasibility. This could be because the startups would find no strategic advantage in such discussion, or because they simply do not have the time or resources for it.

The anthropologist Clifford Geertz turned Goldenweisers involution into agricultural involution in a 1963 book of that title, Agricultural Involution: The Process of Ecological Change in Indonesia. That book, vastly better known than Goldenweisers original essay (and challenged by many critics over the years), applies involution to Indonesian rice paddy farming from the 19th century into the 20th, with Geertz observing how Javanese peasants tried to adapt themselves to a Dutch colonial system that sought to extract value from their land and labor. According to Geertz, agricultural involution happens when farming technology and technique remain at a standstill, even as more labor flows into the system, ultimately yielding ever more complex social arrangements around work. The result is a kind of shared poverty as more and more laborers subdivide the available work. Social arrangements become Byzantine. Where Goldenweiser focused on ritual and aesthetic examples of involution, Geertz used the concept to describe how one kind of innovation, namely shifting social arrangements between peasant workers and landowners, unfolded within the limitations of Javanese agricultures technological standstill. The food-tech nexus that Zimberoff charts displays a different style of involution: technological innovation, to the point of virtuosity, within a larger limiting pattern. Call that pattern our collective difficulty recognizing the political and social character of the food system itself.

Involution is a capacious metaphor. In the work of the anthropologist Xiang Biao, involution (neijuan) describes the predicament of contemporary Chinese society, in which the middle classes and elites are locked in a struggle to pass wealth and advantage on to the next generation: only certain jobs can facilitate this process, and only certain paths of training and accomplishment lead to those jobs. Here the frame or pattern in which involution curls into complexity is determined by the narrow set of conditions for an acceptable life. The social, psychological, and material costs of failure of falling off the social treadmill are very high. Xiang Biaos version of involution shares, with Geertz and Goldenweiser, a sense of stuckness. Every story about involution implicitly conjures a form of change or progress that involution blocks. In Zimberoffs Technically Food, food-tech entrepreneurs pursue value in niches and crevasses that Big Food previously ignored, but rather than progress, their work seems like a desperate effort to keep food habits, forms, and economies afloat as climate change diminishes our available farmland and water. Every strategy in food futurism is a form of imaginative closure. The question facing us in food technology is how to tell innovation from involution and recognize how the two modes feed upon each other.

I have been saving the hardest part for last: when I say that a new food technology counts as innovation or involution, I am making a value claim, just as Goldenweiser and then Geertz and then Xiang Biao have done. But food systems are complex and social things, and political too; an individuals value claim does next to nothing. The challenge is to establish conversations about what human communities find valuable in food. Agreeing about norms is often harder than agreeing about facts. Some approaches to the future of food try to advance individual human health; others try to feed as many as possible, based on their assumptions about what counts as a sufficient diet; others presume that there are natural limits to how many of us can share the planet at once. Why not end with a question: was Reyner Banhams bag of chips a case of innovation or involution? The brilliance of his short essay was to show that the vernacular meaning of industrial foods the curling chip; the bursting, crinkling bag escapes our designs.

Benjamin Aldes Wurgaft is the author of Meat Planet: Artificial Flesh and the Future of Food.

See the original post:
The Involuted Palate, or the Savage Crinkle of Future Snacks - lareviewofbooks

Read More...

Time to Go Sushi With Cellular Salmon; When Pet Owners Tire of Their Minions – The SandPaper

August 17th, 2021 1:51 am

Sushi-loving diners in Callie will soon be partaking of test-tube salmon, compliments of San Francisco-based firm Wildtype. The company touts itself as Building a better food system by pioneering cellular agriculture to grow delicious cuts of our favorite seafood no fishing or fish farming required. I know, just when you think life cant get any weirder.

The companys website hypes its cutting-edge efforts as reinventing seafood, with a clever emphasis on inventing, since the entire process has come about through lab experimentation on handpicked cells of salmon, in the vein of stem cell exploration.

The seeds of Wildtypes chunks seed money has already been gotten aplenty comes via the choicest cells of the finest wild salmon, including king salmon, the finest and fattiest known. Once cells have been adroitly procured, the cellular growing process is on, as the meat of the matter is grown upon a type of organic plant-based scaffolding until done or ripe or something.

The plant-based scaffolding we provide for the cells to grow on, along with all the necessary nutrients like sugars, amino acids, and fats we deliver in solution, allows for the formation of the complex textures that were able to create for all types of sushi products spanning sashimi, nigiri and maki rolls, explains the companys cofounder Ary Elfenbein, a cardiologist and molecular biologist.

Wildtypes test-tube salmon is rather frighteningly identical to the real swimming thing, with a fat composition like the donor fish, including levels of healthy omega-3 fatty acids, but none of the heavy metals, microplastics, parasites, or antibiotics found in most salmon, per the companys website.

One of this methods claims to fame is how it might reduce the need for environmentally suspect fish farming.

Net pens used in fish farming pollute sensitive coastal waterways with concentrated excrement. Many farms have had escape events, introducing invasive species into sensitive ecosystems that compete with local fish populations, company cofounder Justin Kolbeck recently told Forbes magazine.

It should be emphasized this grown-in-house fish product is not even remotely related to soy-based imitation seafood and meats. The end products DNA makeup is salmon all the way; theres simply no energy wasted on the little things, like growing skeletons, scales, internal organs or brains.

Anyone remember the sci-fi thriller The Blob? Just asking for no particular reason.

To buttress Kolbecks point about escape, its profoundly unlikely that a chunk of Wildtype salmon will ooze out of the lab, leaving behind a telltale slime trail along the escape route before seeping seaward to freedom. Of course, should that happen, it would be quite a hook-up sight for any angler reeling in a big chunk of raw salmon meat. Anyone know how to clean this thing? Oh, wait, now that I think about it

OK, should we buy into this New Age salmon meat when it hits close to home? It will hit select market by next month or so, after which the company hopes to eventually produce tons and tons of its highly salmonesque stuff. Also, reports indicate other companies are champing at the test tube to get in on cellular seafood.

Personally, I somewhat prefer my seafood has seen the sea. That said, there is no doubt lab-grown seafood could be a healthy alternative to our overfishing of the worlds oceans. I can even foresee both wild-caught salmon and the beaker-based variety being served at a meal and folks clearly preferring the Wildtype offering, calling the natural too gamey.

As to the early taste tests of freshly picked/harvested Wildtype salmon, even educated buds are giving it flying colors speaking of which, the color of Wildtype salmon is identical to the donor fishs flesh color since it is the exact same fish again with the DNA thing.

For you travelers, if youre out San Fran way, the Wildtype company is all but begging folks to stop on in.

Wildtype wants to establish a high standard of education, trust, and transparency with our customers and the public. We want to show people where their food comes from and how its made, offer the owners.

Ill wax snarky by wondering if it might not be best to place test-tube salmon making in the same realm as, say, scrapple making. Philly folks get my dont ask/dont tell drift.

By the by, there have been some unique growing pains to developing a better bodiless salmon. For some unknown cell binding reason, the first chunks did not take at all well to cooking. The meat broke into what might be called individual component parts hundreds of tiny undefinable pieces of salmon essence. I cant imagine what that would have looked like and I would surely have been the only one in the lab laughing my ass off.

The last I heard, the creative minds of the company are tweaking the growing process so we can someday buy San Fran salmon for more than just sashimi, sushi and sausages.

I will absolutely be among the early-on buyers of salmon a la lab. One problem I see is naming the stuff with full disclosure in tow. There must be a distinct, immediately recognizable terminology. Ill be the first to admit that test-tube salmon would be off-putting. Less so would be manmade salmon or sea-free salmon. The company itself might run with cellular salmon, based on its self-hype that Wildtype is pioneering cellular agriculture to grow delicious cuts of our favorite seafood no fishing or fish farming required.

ECO-UGLY ABANDONMENT: I need to combine two tales in one since both have to do with mankind unloosing nonindigenous species into our delicate Pinelands environment.

The more recent of the two comes via a jungle-ish find by Division of Fish and Wildlife conservation officers. While on patrol, the officers came across your everyday boa constrictor crossing a dirt road. Yes, its everyday if you live in frickin Central America!

The 4-footer was found in a state Wildlife Management Area. Id safely venture to say it was not simply taking in the sights of our outback before making the long slither back to some tropical rainforest.

Forgoing the other minuscule possibility that the boas owner had simply been out walking it only to have his minion slip its leash, this was an all too familiar case of someone ignobly abandoning a faithful critter even after it had dedicated its entire life to being a family-member pet.

OK, that might sound a bit overemotional, but such dump-offs are a lousy trick by incompetent-as-s*** pet owners.

As to what would have become of the tropical snake had it not come back to the road looking for its human buddy, I believe it was Jack London who morbidly suggested that freezing to death isnt the worst way to go. Winter would have ended the snakes unwanted flirtation with untamed freedom.

There was no chance the lone boa could have led to the Pinelands becoming a covey of constrictors even if the captured boa wore a boa, meaning it was a female.

That tale roundaboutly leads to a twinish tale of the time piranhas swam about in Stafford Forge Lake.

It was July 2007 when I got word of weird fish being caught in the historic lake, former home to a forge and cranberry bogs. As I wrote back then, A number of piranhas were recently taken by an angler using Bass Stoppers, a favorite freshwater rig. And these werent minor models of this highly nonindigenous species. One piranha was way hefty.

I recall my well-founded disbelief upon seeing the first photo of the landing. At mere first glance, I knew this hookup was a member of a world-renowned fish family that includes piranha, pacu and oscars. To me, it was clearly a piranha.

So, what in bloody hell was such a species doing in the tannin-laced, temperate zone waters of the Forge?

The answer was all too obvious: Some numbnut had released it after it had outgrown its aquarium and its welcome. Such dumpings, while displaying a touch of compassion when compared to a toilet flush-down, are quite common. In fact, many state waters are now plagued by introduced carp, the leave-behinds from anglers using cheap so-called feeder goldfish to live-line for largemouth bass and pickerel.

The sacrificial goldfish, small carp in essence, either get off the hook or are poured into lakes at the end of a fishing session. They grow rapidly into immense vegetation bottom feeders. Once established, they create such a bottom stir that it can muck up the water, impacting gamefish, which feed by sight. They also inadvertently mosey over bass and sunfish nests hollows in the sand inadvertently sucking up eggs and newborns.

As to the Forge piranhas, the hookups led to an utterly surprising finding that they had surely been there more than just one season. The hardy little devils were showing signs of prospering, likely going into a torpor state when the lake froze in winter. Fears arose as to what they were thriving upon, assuredly indigenous species.

The realization that piranhas were making themselves at home in a New Jersey lake led to fear regarding the many people and pets commonly wading right where the fish were caught. Such frets were a bit unfounded. While packs of piranhas can go gruesomely gonzo over the smell of blood and raw flesh, Ive seen naked native children in Brazil freely swim among them, with nary a single natural bris being reported. Nonetheless, N.J. Fish and Wildlife folks went on one weird-ass search-and-destroy mission by electrocuting the lake. The method shocked the hell out of the lakes inhabitants, causing them to rise woozily to the surface, where any species non grata could be removed and apologies offered to acceptable lake occupants, which quickly recovered from the buzz, all wondering What the hell was that all about?!

RUNDOWN: Weirdly, the blowfish are back in town, mainly the far west side of Barnegat Bay where they had been, then left, only to be replaced by a ton of all new puffers moving in from waters to our north. It is once again possible to best a hundred or more per chumming session.

There are also small weaks and kingfish entering the chum slick.

Weirdest chum-related hookup was a massive black drum estimated by Paul P. at 50 pounds. It was almost landed, net hovering above, before the tiny hook gave way. That is pretty far north for Barnegat Bay black drum.

Speaking of drum, its about time for red drum to make beachline passes. The state record remains at 55 pounds, a fish taken in Great Bay by Daniel Yanino in 1985.

This is an amazing time of year to chum with grass shrimp in places like Myers Hole and surely some deeper waters toward Little Egg Inlet. Such panfishing often offers as great a variety of fish species as youll ever hook during one Jersey sitting.

Considering most of the fish drawn to a shrimp chum will be juveniles, you must use circle hooks and unhook undersized fish as quickly and gently as possible. Best bet is to not even bring them aboard. A nice series of photos can be taken without fish having to pass over the gunnel.

Surfside fluking is fair. Its best when waters are at least a bit roiled. Calm, crystal-clear water periods seem to knock down the flattie action. Every now and again there is a sudsy doormat taken.

Stingrays have glided a bit north, though a few are still quite obvious along the clear-water shoreline. Ive gotten two emails regarding ways to cook ray wings. Ill give them a try. If my taste buds salute, Ill pass them on.

Triggerfish are making their typical late-summer presence known. Some nice-sized ones mixed in, way larger than they usually show down south, re-begging the question of whether these fish go back to the Deep South or move off shore for the winter. The average sheepshead size up here dwarfs the typical sheepsheads in places like the Indian and Banana rivers in Florida.

Please do not try to fillet triggers. Too much meat is utterly wasted. After gutting, simply cook them whole. Once done and they bake very quickly with skin still on pull off the now easily removed skin and dine on the delicate white meat within. Of note, there are some filefish being labeled triggerfish. They are different to a degree, but are surprisingly similar in taste.

jaymann@thesandpaper.net

Read the original here:
Time to Go Sushi With Cellular Salmon; When Pet Owners Tire of Their Minions - The SandPaper

Read More...

Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India -…

August 17th, 2021 1:51 am

This article was originally published here

Transfus Med. 2021 Aug 15. doi: 10.1111/tme.12805. Online ahead of print.

ABSTRACT

BACKGROUND: Haematopoietic stem cells (HSC) may act as a source of infection for the recipient due to manipulation at multiple levels from collection to infusion. Due to the high risk of contamination cultures are usually taken during multiple steps. The clinical significance of microbial contamination of HSC on the post-transplant course and the role of prophylactic antibiotics is relatively unknown.

AIMS AND METHODS: The aim of our study is to investigate the incidence of microbial contamination of haematopoietic stem cell and to assess its impact on the post-transplant febrile neutropenia, engraftment kinetics, hospitalisation and day 100 mortality. Details of all patients admitted in the bone marrow transplantation unit of a tertiary care centre in India between January 2014 and December 2018 were collected from case records.

RESULTS: Of the 1306 stem cell harvests from 503 patients sent for culture, 17 harvests (1.3%) were found to have a culture positive report. Sixteen patients had undergone autologous transplant. Multiple myeloma was most common indication of HSC transplant followed by Non-Hodgkin Lymphoma (NHL). Twelve of 17 HSC cultures were positive at the time of infusion and five were positive at the time of harvest. The five HSC that were culture positive at the time of harvest were culture negative at the time of infusion. Gram-positive organisms were isolated in six cultures and gram-negative in rest. All patients developed febrile neutropenia post-transplantation between day 1 and day 7. The median time of onset of fever was day +5 (1-7), the median duration of fever was 4 days (2-7), the median duration of antibiotic use was 11 days (9-16). Median day for neutrophil engraftment was 11 days (9-16), the median day for platelet engraftment was 14 days (10-25) and median duration of hospitalisation was 15 days (12-78). All patients were alive at day 100 of transplant.

CONCLUSION: This study shows that there appears to be minimal impact of culture positive HSC on transplant related outcomes in terms of engraftment kinetics, duration of hospitalisation and day 100 mortality. Discarding of contaminated HSC may not be required, though on development of febrile neutropenia appropriate antibiotics should be administered based on sensitivity pattern of HSC culture. Larger prospective studies are needed to determine the clinical relevance of such contaminations. Emphasis should be laid on better infection control practices to minimise contamination rates.

PMID:34396610 | DOI:10.1111/tme.12805

Read the original here:
Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India -...

Read More...

Longeveron: Time to Buy the Di – GuruFocus.com

August 17th, 2021 1:50 am

Longeveron Inc. (LGVN, Financial) is an emerging clinical-stage biotechnology player that utilizes stem cell research. It is working towards developing regenerative medication via allogeneic mesenchymal stem cells. It is in the progress of building a number of cellular therapies at its facility, utilizing healthy bone marrow of adult donors to develop treatments for aging and aging-related diseases like Alzheimers Disease.

The companys lead candidate is a therapy known as Lomecel-B, an allogeneic product containing medicinal signaling cells from the adult donor bone marrow (from an 18 to 45 age group) and culture expanded in the companys cell processing facility. They identify and use cells with regenerative properties to build a therapy that could carry out various functions, including tissue repair and organ maintenance.

Longeveron has been in the news recently as it released the data of the Phase 2b aging frailty trials for Lomecel-B. The results did not live up to expectations, causing the stock to plunge. However, the long-term prospects of the company have not changed, in my opinion, which could mean now is a great opportunity to buy the dip.

The Phase 2b trial data

Longeveron carried out a multi-center study to assess the effect of its lead candidate Lomecel-B therapy on 148 random subjects. Its trial was partially funded by an SBIR (Small Business Innovation Research) grant from the National Institute of Aging. The company carried out a single peripheral intravenous infusion of the lead candidate in various quantities ranging from 25 million to 200 million cells. It kept the subjects under observation for 52 weeks to evaluate the efficacy and safety of the therapy. The management performed a six-minute walk test on the subjects to assess their exercise tolerance and endurance in order to evaluate the impact of the treatment. This test also analyzed gait speed, short physical performance battery, grip strength, performance-oriented mobility assessment, sexual function, cognition, depression and other factors associated with the subjects in their daily lives.

Longeveron did not see statistically significant results compared to the placebo after 180 days, which is what has disappointed investors and led to the recent selloff. However, the management saw a significant difference from placebo after 270 days of the treatment. Moreover, Lomecel-B continues to demonstrate a high level of safety as no patients showed signs of any severe adverse conditions.

The information is sufficient for Longeveron to continue pursuing their research aggressively, not just in the U.S. but in other countries as well. The management aims to initiate the Phase 2 Japanese Aging Frailty trial this year while waiting for the results of Phase 1/2 HERA trial data. The 'HERA' trial data is expected to evaluate the effects of Lomecel-B on the immune response to influenza vaccination in Aging Frailty subjects.

The importance of aging and frailty research

Aging Frailty-oriented research is gaining a very high amount of importance because of its substantial addressable market. Most patients who suffer from it show symptoms like muscle loss and decreased strength, low-level activity, slow walking, poor energy level and endurance, weight loss, nutritional deficiencies and fatigue. It has a negative impact on muscle and bone tissue health. Apart from muscles and bones, aging and frailty also negatively affects the cardiovascular system, immune system and cognition.

Stem cell treatments for aging-associated diseases are a crucial area of research given the ageing population. However, there are no FDA approved stem cell treatments in the U.S. within this domain. The potential addressable market for aging and frailty is rising sharply due to the gradual increase in average life expectancy as well as declining birth rates. Longeveron is one of the key movers in this domain and has shown significant results through their Lomecel-B therapy trials.

While the trials may not have shown a statistically significant result in a 180-day period, the 270-day data is extremely encouraging for the companys future. Furthermore, if the Lomecel-B trials continue to show success in the upcoming quarters, Longeveron could become a top candidate for a large pharma acquisition.

Is the crash justified?

Longeverons stock crashed after the companys Phase 2b press release came out, but is this crash justified? The trial results may not have been positive for a 180-day time horizon as hoped, but the 270-day results have been encouraging. Moreover, given the fact that the safety of Lomecel-B has been unquestionable, this implies that the company can go ahead with other trials (including the Phase 2 trial for aging and frailty in the Japanese market) with great confidence.

There is also a huge upside potential with respect to the future prospects of Lomecel-Bs application in Alzheimers Disease and other ageing-related diseases. Last but not the least, the company has sufficient cash to go through with multiple trials across different geographies. Thus, I believe that the recent crash in Longeverons stock price is no reason for investors to panic. Moreover, biotech microcap investors with a high risk appetite could see this drop as an investment opportunity.

See the rest here:
Longeveron: Time to Buy the Di - GuruFocus.com

Read More...

Page 179«..1020..178179180181..190200..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick